

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Chronic lymphocytic leukemia (CLL); hairy cell leukemia	CD160; CD23; CD5	<p>Human studies suggest CD160 expression could help diagnose CLL. In mature and immature B cells from CLL patients, CD160 expression was higher than that in B cells from healthy controls and patients with other hematological malignancies. A diagnostic that measured levels of CD160 diagnosed CLL with 95% specificity and 100% sensitivity, and the ratio of CD23 to CD5 distinguished the hairy cell subtype from other types of CLL. Future studies could include using the CD160-based diagnostic in clinical trials of CLL therapies.</p> <p>MAT302, an anti-CD160 antibody from MAT Biopharma S.A., is in preclinical testing to treat solid tumors.</p> <p>SciBX 4(28); doi:10.1038/scibx.2011.790 Published online July 21, 2011</p>	Patent and licensing status unavailable	<p>Farren, T.W. <i>et al. Blood</i>; published online June 28, 2011; doi:10.1182/blood-2011-02-334326</p> <p>Contact: Samir G. Agrawal, Barts and The London NHS Trust, London, U.K. e-mail: s.g.agrawal@qmul.ac.uk</p>